(Q54307476)

27 May 2018

title

Nintedanib: first global approval. (English)

1 reference

27 May 2018

main subject

nintedanib esylate

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Paul L McCormack

1

1 reference

27 May 2018

publication date

1 January 2015

1 reference

27 May 2018

published in

Drugs

1 reference

27 May 2018

volume

75

1 reference

27 May 2018

issue

1

1 reference

27 May 2018

page(s)

129-139

1 reference

27 May 2018

https://scigraph.springernature.com/pub.10.1007/s40265-014-0335-0

exact match

0 references

cites work

Novel therapeutic approaches for pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0335-0

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

21 January 2018

1 reference

12 December 2020

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

1 reference

12 December 2020

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer

1 reference

12 December 2020

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer

1 reference

12 December 2020

10.1007/S40265-014-0335-0

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018